Trial Profile
Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ADJORL1
- 24 Oct 2023 Results (n=57) assessing 2-year disease free survival and overall survival in in head and neck cancer squamous cell carcinoma patients, presented at the 48th European Society for Medical Oncology Congress.
- 04 Apr 2022 Status changed from not yet recruiting to recruiting.
- 17 Jan 2018 New trial record